Goërtz et al. assessed 2113 patients with confirmed or suspected COVID-19 diagnosis and found that at least 87% of them continued with symptoms later than 60 days of the first symptom (of which 32% reported one or two symptoms and 55% reported three or more symptoms) 
. The conditions (up to 60 days) following infection with COVID-19 are known as prolonged, long-lasting, post-acute, long-term, or chronic effects; among them, the most common symptoms are fatigue, dyspnea, and insomnia 
. Vitamin D deficiency has also been related to all these symptoms 
. Carpagnano et al. found a high prevalence of vitamin D deficiency in COVID-19 patients with acute respiratory failure 
. It is important to emphasize that vitamin D deficiency is related to many other diseases and conditions that will increase the risk of developing a long-term COVID-19 
. In this respect, Savanelli et al. reported that vitamin D deficiency is the greatest predictor of the prevalence of dyslipidemia and hypertension in patients with coronary heart disease, suggesting the presence of both factors in cardiovascular risk in this group of patients 
. Furthermore, according to a recent review, this virus may provoke a new onset of type 2 diabetes mellitus with undetermined clinical and metabolic components, providing a possible role for COVID-19 in developing type 2 diabetes mellitus 
2. Long COVID-19 and Vitamin D
The pandemic’s beginning with COVID-19 was characterized by a great concern to contain the contagion of the disease. Almost two years after the health emergency was declared, the focus is the health of those who have survived the disease 
. As of 18 February 2022, over 409 million confirmed cases and over 5.8 million deaths had been reported globally 
These data highlight the large number of people who had COVID-19 and have recovered; in some of them, the consequences will persist in the long term. It is estimated that one-third of patients have persisting symptoms for six months after contracting the infection 
. Thus, there is an increased need to provide healthcare for long-term symptoms.
The risk factors for long COVID-19 differ somewhat from those for COVID-19 
. One study reported that having hypertension, obesity, a psychiatric condition, or an immunosuppressive condition was associated with increased risk of long COVID-19 
. On the other hand, long COVID-19 is more likely in women and the age group most affected is somewhat lower. One reason for middle age being a more important risk factor for long COVID-19 is that the risk of mortality increases rapidly with increasing age. A review of COVID-19 mortality rates for 66,646 inpatients in the U.S. admitted from April to June 2020 found increasing mortality rates with increasing age: 40–49 years, 5.8%; 50–59 years, 10.6%; 60–69 years, 18.0%; 70–79 years, 26.5%; and 80+ years, 34.4% 
. For both COVID-19 mortality and long COVID-19, admission to an intensive care unit is a very important risk factor. Thus, the difference in age profile between mortality and long COVID-19 is that older COVID-19 patients are more likely to die. The reason for more women having long COVID-19 is also likely due to men having a higher mortality rate from COVID-19.
A study involving 4182 COVID-19 cases from Sweden, the UK, and the USA investigated the risk factors for long COVID-19 
A total of 558 participants reported symptoms lasting longer than 4 weeks, 189 > 8 weeks, and 95 > 12 weeks. Factors significantly associated with long COVID-19 were age (52 (43–59) years), asthma, heart disease, visit to a hospital, and number of symptoms.
A review of risk factors for long COVID-19 stated that several biomarkers were elevated including D-dimer, interleukin-6 (IL-6), C-reactive protein, procalcitonin, and neutrophils count 
. A study conducted in western Mexico involving 22 vitamin D supplemented COVID-19 outpatients (mean 25OHD = 22.4 ng/mL) and 20 non-supplemented patients (mean 25OHD = 23.4 ng/mL) found that, although ferritin concentrations were significantly lower in supplemented patients, d-dimer concentrations were not significantly different 
. A study in India also reported no significant effect on d-dimer concentrations with vitamin D supplementation of 69 COVID-19 patients 
. Additionally, a high-dose vitamin D supplementation study conducted in Turkey involving 95 hospitalized COVID-19 patients found that increasing mean 25OHD concentration from 23 to 35 ng/mL had no significant effect on ferritin, d-dimer concentrations, but was associated with reduced fibrinogen concentrations 
Epstein–Barr virus (EBV) reactivation appears to be a risk factor for severe COVID-19 and also appears to be associated with long COVID-19. A study in the UK involving 128 COVID-19 patients, 17 had EBV reactivation and more severe COVID-19 and adverse outcomes 
. A study in Turkey found long COVID-19 in 56 of 185 COVID-19 patients and that 20 of 30 long COVID-19 patients were positive for EBV reactivation vs. 2 of 20 controls 
. Vitamin D supplementation of 20,000 IU/week over 96 weeks was found to significantly reduce humoral immune responses to the latent EBV antigen EBNA1 in relapsing-remitting multiple sclerosis 
One of the reasons why vitamin D supplementation may be ineffective in treating long COVID-19 is that the SARS-CoV-2 virus can downregulate vitamin D receptors. This has been observed for cytomegalovirus infection 
, hepatitis B virus 
, and hepatitis C virus 
. EBV has been found to block activation of gene expression through is EBNA-3-ptotein 
. If downregulation is not complete, it might be that very high vitamin D doses would be able to have some effect, but not in the cells with VDRs downregulated.
Although many of the multi-organ manifestations of COVID-19 are known, the possible long-term implications remain unknown 
. Given the recentness of the COVID-19 pandemic, it is not possible to estimate, by itself, the long-term effects. However, there are similar coronavirus events that have happened previously, such as SARS-CoV-1 and Middle East respiratory syndrome coronavirus 
. Although the current COVID-19 has lower mortality rates than those mentioned above 
, the reports describe similarities, allowing to know the possible long-term implications and thus take actions to minimize complications 
. Some of the long-term manifestations of these other pandemics were: matched exercise capacity and carbon monoxide diffusing capacity, cardiovascular complications, hematological manifestations, thrombotic complications, central nervous system manifestations, and renal and gastrointestinal complications 
Wang et al. stated that COVID-19 could leave long-lasting consequences in at least three critical areas: pulmonary, neuronal, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis 
A recent study based on survivors of COVID-19 found that 78 patients out of 100 who had recovered had abnormal cardiovascular findings on magnetic resonance imaging; also, 36 of them suffered dyspnea and unusual fatigue 
. It should be noted that these consequences were not only observed in those patients who had a severe illness but also in those with mild and moderate presentations 
. Many questions remain unanswered, but the variation in viral load and differential immune response can explain why some have long COVID-19 and others do not 
. Ahearn-Ford et al. presented data that proposed that inflammatory cytokine pathways altered during infection could continue during convalescence 
A recent review stated that the effects on the central nervous system after an acute phase of COVID-19 could be perpetuated over time as a neuro-COVID-19. They reported 12 neurological deficits in long COVID-19, such as mental fog, tremors, confusion, and stiff limbs 
. For their part, Logue et al. investigated the symptoms that persisted after COVID-19 infection in a longitudinal prospective cohort study with 234 patients. The results show that the most persistent manifestations were fatigue (13.6%) and loss of the sense of smell or taste (13.6%) 
The importance of vitamin D in long COVID-19 has recently been published 
. This pro-hormone, fat-soluble is obtained to a greater extent through sun exposure, but there is also a lower contribution from diet 
. Diet is an essential determinant of 25OHD concentrations. In particular, Crowe reported that 25OHD concentrations were higher in meat and fish eaters than in vegetarians and vegans, who exclude specific food sources of vitamin D from their diet 
. More recently, a positive association has been reported between 25OHD concentrations and adherence to the Mediterranean diet, a nutritional pattern effective in preventing and treating obesity-related diseases due to the synergistic action of many nutrients with anti-inflammatory and antioxidant properties 
. The best-known function of this vitamin is related to the normal mineralization of the bones since it contributes to the absorption of calcium in the intestine and the maintenance of adequate levels of calcium and phosphate in serum, having a fundamental role in the prevention of rickets in children and osteomalacia and osteoporosis in adults 
The possibility of vitamin D acting as an immunomodulator has generated great interest recently 
. However, it has many other functions, including the modulation of cell growth, neuromuscular function, immune function, and a reduction in inflammation 
. It is important to note that 25OHD concentrations can be decreased in the presence of acute inflammation.
Likewise, more studies are needed to understand better the health impact of the prolonged period of COVID-19 in these patients. Before the pandemic, it was already known that low 25OHD concentrations were associated with fatigue and muscle weakness in the general population. Townsend et al. investigated the relationship between 25OHD concentrations and fatigue and reduced exercise tolerance in 149 patients 79 days after COVID-19 
. They evaluated the participants using the Chalder Fatigue score, six-minute walk test, and the modified Borg scale. By applying multivariable linear and logistic regression models, they concluded that there was a correlation between vitamin D and persistent vitamin D fatigue and reduced exercise tolerance in this population of COVID-19 patients. It is important to note that this work only evaluated two of the ample diversity of long COVID-19 symptoms 
. However, fatigue is the most common symptom of long COVID-19 and is seen in other viral infections 
Pizzini et al. studied, in a prospective, multicenter study on long-term sequelae after suffering COVID-19 in 109 patients, the associations of 25OHD concentrations with the presentation of COVID-19 
. It was observed that a high proportion of patients presented alteration of vitamin D metabolism eight weeks after diagnosis. Patients with severe COVID-19, most likely due to prolonged hospitalization, showed a disturbing parathyroid-vitamin-D axis within their recovery phase. However, low 25OHD concentrations were not related to the burden of persistent symptoms, concluding that although vitamin D deficiency is common among COVID-19 patients, it was not associated with long-term disease outcomes 
. Due to the novelty of the disease and the different reported results, it is essential to continue with more studies to evaluate the possible effect of vitamin D in the long post-COVID-19 period.
Overall, the COVID-19 pathology is still characterized by cytokine storm, resulting in endothelial inflammation, microvascular thrombosis, and multiple organ failure 
. Hyperinflammation is a critical component of severe COVID-19, which is associated with poor outcomes underneath the cytokine storm umbrella term 
. Thus, an important way to minimize or avoid long COVID-19 is to raise 25OHD concentrations before SARS-CoV-2 infection or COVID-19.
Another way to reduce the risk of long COVID-19 is to aggressively treat SARS-CoV-2 infection and COVID-19 as soon as possible after symptoms are manifest. In one study, raising serum 25OHD concentrations to a mean value near 35 ng/mL in a few days to two weeks for hospitalized COVID-19 patients significantly reduced mortality rates but did not seem to affect symptoms 
. On the other hand, treating hospitalized COVID-19 patients with high-dose calcifediol has been found to significantly reduce admission to the Intensive Care Unit and death rates 
It should be noted that most of the research results are based on COVID-19 variants that are no longer dominant such as the Delta variant. The Omicron variant is associated with 30–45% lower attendance for emergency care and 50–70% lower hospital admission rate in the UK than the Delta variant was 
. A preliminary report from South Africa also indicates that Omicron COVID-19 is much less severe than Delta COVID-19 
. Oxygen therapy use was 75% lower, mechanical ventilation use was nearly 90% lower, admission to intensive care units was about 40% lower, length of stay was 70% lower, and death rates were 90% lower. Although the mean age of Omicron COVID-19 patients (36 years vs. 59 years for Delta COVID-19 patients) explains some of the differences, it implies that those who survived Omicron COVID-19 are much less likely to experience serious long COVID-19. However, it is too soon to determine whether this will be the case.